NSRGF Stock Recent News

Reiterating my Buy Rating on Nestlé driven by dividends as its main investment case and a potentially bottoming share price. Nestlé faces challenges from reduced pricing power and FX headwinds, yet maintains relatively robust volumes. Nestlé's rising debt, while concerning, remains manageable. Valuation analysis shows a significant discount, making it an attractive buy with a 4% dividend yield.

Including high dividend yield companies that pay sustainable dividends in your dividend portfolio can bring a number of benefits. In this article, I will introduce you to 10 high dividend yield companies to consider investing in for January 2025. The selected companies not only offer a relatively high Dividend Yield, but also an attractive Valuation and potential for dividend growth.

Sarat Sethi, Managing Partner at DCLA, joins CNBC's "Halftime Report" to explain why he's buying more Nestle

Nestle's share price is at a six-year low, offering a 4% dividend yield, presenting a potential entry point for value investors. Nestle's extensive brand portfolio, strong market presence, and robust cash generation make it a stable, defensive investment with limited downside risks. New CEO Laurent Freixe's experience and realistic growth targets, combined with potential efficiency improvements, could drive future growth and profitability.

Nestle has had a pretty woeful 2024, consistently missing consensus on organic sales growth while cutting guidance on several occasions. Management reset margin expectations at the company's recent Capital Markets Day. While fresh guidance looks underwhelming, the company should be free to push on from here. The ADSs are down roughly 30% year-to-date. Nestle only needs to deliver very modest free cash flow growth to justify the current price.

Nestle has stepped up its response to the launch of weight-loss drugs with a range of protein shots and drinks that it says can have the same impact. Boost Pre-meal is a liquid shot that will “support people using GLP-1 receptor agonists or other weight-loss medications”, said the Kit Kat maker.

Nestle is launching protein shots in the United States which it says help suppress appetite for people looking to shed pounds, the latest effort by the world's biggest packaged food maker to tap the booming market for weight-loss products.

Former Nestle and Fresenius SE CEO Mark Schneider could succeed Jim Hagemann Snabe as chairman of the supervisory board of Siemens by 2027 at the latest, Siemens said on Wednesday, proposing Schneider's election.

Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high risk of life-threatening bacterial infections

GENEVA--(BUSINESS WIRE)--Lucien Selce and MKT Capital Ltd. (together, “we”), who collectively own 1.4 million shares of Seres Therapeutics Inc. (NASDAQ: MCRB) (“Seres” or the “Company”), today published the following open letter to the Company's Board of Directors (the “Board”). *** September 27, 2024 Members of the Board, We are writing to you today as a stockholder of Seres who is seeking additional information regarding the Company's planned sale of its VOWST business to Nestlé Health Scienc.